FDA approves long-delayed global sunscreen ingredient bemotrizinol—revealing US regulatory lag, corporate influence, and racial disparities in skin cancer prevention
Original framing: “First new US sunscreen ingredient since 1999 approved by FDA – a skin scientist explains how bemotrizinol works” — The Conversation - Global
The FDA’s 24-year delay in approving bemotrizinol reflects a historical pattern of risk-averse regulatory behavior, including the 1978 sunscreen monograph process that prioritized incremental updates over innovation. This inertia is compounded by the agency’s reliance on industry-funded safety data, which has historically excluded marginalized populations, such as darker-skinned individuals, from clinical trials.
The FDA’s belated approval of bemotrizinol exposes a systemic failure where regulatory caution, corporate lobbying, and racial bias intersect to delay life-saving public health innovations.
For 24 years, the US market languished under a sunscreen monograph that prioritized the interests of legacy manufacturers like L’Oréal and Estée Lauder over the needs of consumers, particularly those with darker skin tones who were excluded from clinical trials. This case mirrors historical patterns of institutional inertia, such as the FDA’s 1978 monograph process, which codified outdated standards while ignoring global advancements. The trickster’s irony lies in how a system designed to 'protect' health became a barrier to it, as seen in the absurdity of blocking a globally vetted ingredient while allowing less effective alternatives to dominate. Moving forward, solutions must address regulatory capture, racial inequities in research, and the devaluation of traditional knowledge—transforming bemotrizinol’s approval from a belated correction into a catalyst for systemic change in global health governance.